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Background: Recent studies have demonstrated that synthetic dsRNAs may produce therapeutic effects in a
target-independent manner through stimulation of the toll-like receptor-3 (TLR3)/interferon pathway; as a result,
angiogenesis and proliferation of tumor cells are inhibited. Thus, this pathway may become a potential target of
dsRNA in tumor suppression. In this study, we evaluated the role of synthetic dsRNA as a TLR3 synergist and by
combining with sorafenib in anti-hepatocellular carcinoma (HCC) in vitro and in vivo.
Methods: Four dsRNAs were designed and synthesized. One of them that was capable of activating TLR3 most
effectively in human HCC cell line (HepG2.2.15) was selected as a TLR3 synergist (called BM-06). Subsequently, the
expression of proteins relating to TLR3 signaling pathway, such as NF-κB, caspase 8 survivin, bcl-2 and PCNA
affected by BM-06, sorafenib alone or in combination, was compared. The migration, proliferation and apoptosis of
HepG2.2.15 cells were evaluated in presence of BM-06, sorafenib alone or in combination of both. The similar
treatments were also applied in an SD rat primary HCC model.
Results: qRT-PCR data showed that the expression of TLR3 and NF-κB in HepG2.2.15 cells was enhanced. BM-06
was selected as a TLR3 synergist capable of activating the TLR3/interferon pathway most effective among 4
synthetic dsRNAs. The migration and proliferation were significantly inhibited in treated HepG2.2.15 cells with
BM-06 or Sorafenib alone as compared with PBS-sham control (P < 0.01). However, the role of combination BM-06
with Sorafenib was the most prominent. Tumor cell apoptotic rate was increased by BM-06 or combination when
compared to PBS or poly(I:C) (P < 0.05). Similarly, in orthotopic HCC SD rats, the effect of the combination was
superior to either agent alone on the inhibition of tumor growth and induction of HCC cell apoptosis (P < 0.05).
Conclusions: dsRNA alone was capable of inhibiting the proliferation of HepG2.2.15 cells and tumor growth of
orthotopic HCC SD rats, but the effect of combination of dsRNA with sorafenib was more prominent. These
findings implicate the potential role of combined use of a dsRNA, a TLR3 synergist, and sorafenib in inhibition of
HCC.
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Hepatocellular carcinoma (HCC) is a complex and hetero-
geneous tumor with several genetic alterations. It is the
second leading cause of cancer deaths in man and the
sixth in women worldwide [1-3]. An estimated 748,300
new liver cancer cases and 695,900 liver cancer deaths
occurred in 2008 [4]. However, mechanisms of initiation
and progression of liver cancer have not been elucidated
completely. Long-term survival rate remains unsatisfactory
due to tumor recurrence and limited response to chemo-
therapy and radiotherapy [5]. Clinically, 70-90% of HCC
cases develop due to a background of cirrhosis or chronic
liver inflammation [6]. So far, there is a lack of effective
systemic therapy for advanced cases. Only 10–20% of
HCC patients in China are able to undergo surgical resec-
tion due to poor liver function or advanced disease [7]. In
the West, 40% of patients can receive potential curative
treatment (resection, transplantation, or local ablation)
and 20% are suitable for chemoembolization [8-10].
Therefore, development and identification of novel agents
that are able to suppress HCC effectively is imperative for
advanced HCC patients. The advent of sorafenib and syn-
thetic dsRNAs increases chemotherapeutic options for
these advanced patients.
In the past years, sorafenib, a multi-kinase inhibitor,
represents a breakthrough in the management of this neo-
plasm [11]. It is a bi-aryl urea capable of inhibiting mul-
tiple receptors of tyrosine kinases (RTK) and Ser/Thr
kinases [12]. These include but are not limited to all iso-
forms of Raf, all isoforms of vascular endothelial growth
factor receptors (VEGFR), and platelet-depedent growth
factor receptor (PDGFR)-β. This multifunctional profile
lends itself to inhibition of tumors via the Ras/Raf/MEK
pathway, activation and proliferation of endothelial cells
via VEGFR-2 and the Ras/Raf/MEK pathway, recruitment
of pericytes via PDGFR-β (required for vessel stabilization
and maturity), recruitment of stabilizing stromal cells to
the tumor’s parenchyma, as well as subsequent stimulation
of stromal cells through growth factors [12-14]. The above
effects of sorafenib are similar to that observed with rastu-
zumab in breast cancer, bevacizumab in colon cancer, and
erlotinib in lung cancer with a decrease in the risk of death
in the range of 25%-35% [15-17]. The above evidence that
increase the efficacy of molecular targeted therapies for
liver cancer has triggered a search for additional molecular
agents to further prolong patient survival.
TLR3, a member of the Toll-like receptor (TLR ) fam-
ily, can recognize double-stranded RNA (dsRNA) from
viruses, endogenous dsRNA released from dying cells, or
synthetic dsRNA such as polyriboinosinic:polyribocy-
tidylic acid (poly I:C). TLR3 signaling depends solely on
the TLR TIR domain which contains the adaptor-
inducing IFN-ß (TRIF) adapter protein. This leads to ac-
tivation of the NF-κB and IRF3 transcription factors,and as a result, induces the antiviral interferon response
[18,19]. Furthermore, TRIF itself exhibits proapoptotic
activity, suggesting that TLR3 signaling can trigger cell
death pathway [20]. Recently, the TLR3 ligand dsRNA
has been reported to induce apoptosis in several cell
types through multiple pathways. In addition, TLR3 may
directly trigger apoptosis in certain cancer cells [21,22].
In addition, TLRs in tumor cells facilitate their evasion
from immune surveillance via the suppression of T-cell
proliferation and natural killer cell activity, suggesting
that TLR signaling in tumor cells is associated with the
progression of cancer and evasion of host defenses.
Thus, TLRs could be considered as potential therapeutic
targets in HCC.
Due to the complexity of genetic aberrations in HCC,
single agent often fails to suppress tumor growth com-
pletely; therefore, combination of two or more anti-
cancer agents would greatly increase therapeutic effects..
In this study, we evaluated the expression of a series of
proteins relating to TLR3 signaling pathway, such as
NF-κB, caspase 8 survivin, bcl2 and PCNA, affected by
dsRNA or sorafenib alone or in combination of both.
According to the sequence of TLR3 sensitive virus, 4
dsRNAs were synthesizede, and only one was selected as
a TLR3 synergist (BM-06) since it was the most effective
to activate TLR3. Our results showed that combination
of BM-06 with Sorafenib was superior to either agent
alone in the inhibition of tumor growth either in vitro
HCC cell lines (HepG2.2.15) or in vivo HCC rat models.
Future investigations will be focused on the mechanism
of the activated TLR3 in inhibiting HCC, and ultimately,
a more effective anti-HCC therapy will be evaluated
using a combination use of sorafenib and dsRNA.Methods
Cell culture
Human HCC cell line (HepG2.2.15) producing HBV was
purchased from Ruijin Hospital (Shanghai, China). The
cells were maintained in a Dulbecco’s modified Eagle’s
medium (DMEM) (GibCo BRL, Grand Island, NY, USA)
supplemented with 20% fetal bovine serum (FBS),
2 mM L-glutamine, and 100 U/mL penicillin-streptomycin
mixture (GibCo BRL, Grand Island, NY, USA) at 37°C and
5% CO2 in a humidified chamber.Design and syntheses of 4 dsRNA TLR3 synergists
Four dsRNAs were designed and synthesized by Bio-
mics.Co. Ltd (Nantong, China). Their antisense se-
quences are as follows: BM-06: CCGGCCCCUGAAU
GCGGCUAAUC; VEGF-siRNA: GAUCCGCAGACGU-
GUAAAUdTdT; VEGFR-siRNA: GAGUGUAAAAACA
UUUGAAdTdT; short (17nt)-dsRNA: GUCCUACUGA
UUGAAGU.
Table 1 The primer pairs used in the PCR performing

















* Primer pairs were designed for human (H) HepG2.2.15 cells; and # Primer
pairs designed for rat (R) HCC tissues.
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culture plate and allowed to grow until 80% confluence.
Subsequently, these cells were treated with the above 4
different dsRNAs, respectively. (10 μg/ml)After treat-
ment at 37°C for 24 hours, the mRNA and protein ex-
pressions of TLR3 and NF-κB in HepG2.2.15 cells were
measured by qRT-PCR and Western blot, respectively.
The dsRNA that showed the most effective activation
against TLR3 /interferon pathway was selected for fol-
lowing interventional treatments.
Treatments of HepG2.2.15 cell line
HepG2.2.15 cells were incubated with the synthetic
dsRNA (BM-06), or sorafenib (Bayer) alone, or BM-06
plus sorafenib. In the present study, poly(I:C) (Invivogen
San Diego, USA) and phosphate buffered saline (PBS)
were used as a positive and a negative control, respect-
ively, by replacing dsRNA or sorafenib. Sorafenib obtained
from Nantong Tomor Hospital in the commercially avail-
able form of 200 mg tablets was dissolved in 100% DMSO
on the day of treatment. Both dsRNAs and sorafenib were
incubated with cells at a concentration of 10 μg/ml for
24 hours in in vitro experiments.
Development of orthotopic HCC SD rat model and drug
treatment
Forty male Sprague–Dawley (SD) rats, 4–6 weeks old and
weighing 120–160 g, were fed with food containing 0.03%
2-acetylaminofluorene (2-AAF, Sigma), a HCC carcinogen,
for 16 weeks in an air-conditioned environment. Thirty-
five rats were randomly divided into 5 groups (n = 5/
group): dsRNA, sorafenib, Poly I:C, dsRNA plus sorafenib
and PBS control. Two of the remaining ten rats were eu-
thanized at each time point of 12, 14, 16 ,18 and 20 weeks,
respectively, to decide cellular malignant transformation
in the livers. All rats were treated and all procedures were
conducted in accordance with the guidelines for experi-
mental animals approved by the Animal Care and Use
Committee of Nantong University, P.R. China.
Solublized sorafenib was administered intraperitoneally
(i.p.) into HCC rats, once a week, at 20 mg/kg. dsRNA
and poly(I:C) were suspended in sterile PBS and injected
(i.p.) into rats with HCC, once a week, at 1.0 mg/kg. Ad-
ministration started at 16 weeks after the rats were fed
with 2-AAF, and continued for 6 weeks. At the end of
treatments, all treated rats were sacrificed, the liver was
collected and weighed. Part of the liver tissue was fixed in
10% formalin for pathological examination and immuno-
histochemical analysis, and the remaining were stored
at −80°C for RNA and protein extraction.
qRT-PCR
Total RNA was isolated from HepG2.2.15 cells and rat
HCC liver tissues using TRIZOL (Invitrogen, Carlsbad,CA). qRT-PCR was performed to evaluate TLR3, NF-κB
caspase-8 and IFN-γ using an ABI 7700 Sequence De-
tection Systerm (Applied Biosystems). caspase-8 and
IFN-γ were measured only in rat HCC tissues. Cycling
conditions for amplification were: 95°C for 3 min; 35 cy-
cles at 95°C for 45 s, 60°C for 45 s, and 72°C for 30 s;
and terminated at 72°C for 7 min. The primer pairs were
listed in Table 1. All human gene expression was nor-
malized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA copies, and rat gene expression was
normalized to β-actin mRNA copies in all samples.
Immunofluorescence
Cells were incubated with a rabbit polyclonal anti-NF-κB-
p65 antibody (Table 2) at a dilution of 1:100 as the pri-
mary antibody. A goat anti-rabbit IgG conjugated with
FITC (Table 2) was used as the secondary antibody at a
dilution of 1:100. Samples were counterstained with
Hoechst 33258 and photographed using a confocal micro-
scope (Olympus, BX51, Japan).
Cell proliferation assay
Cell proliferation was measured using the Cell Counting
Kit-8 (CCK-8) (Dojindo, Kumamoto, Japan) assay follow-
ing manufacturer’s instructions. Briefly, HepG2.2.15 cells
were seeded on a 96-well cell culture cluster (Corning
Inc., Corning, NY) at a number of 2 × 104/well in a vol-
ume of 100 μl, and allowed growing overnight. Next day,
CCK-8 reagents were added to each wells under differ-
ent treatments and incubated at 37°C for 2 hours.
Table 2 The antibodies used in immunohistochemical staining and Western blot
Antibody Producer Applications Working dilutions Positive localization
TLR3 Abcam Western blot 1:1000 cytoplasmic
1:100
NF-κB p65 Cell Signaling Technology Western blot Immunofluorescence 1:1000 cytoplasmic
1:100 nucleus
Lamin B Santa Cruz Biotechnology, Western blot 1:100 nucleus
α-tubulin Santa Cruz Biotechnology, Western blot cytoplasmic
Survivin Santa Cruz Biotechnology Western blot 1:1000 cytoplasmic
PCNA Santa Cruz Biotechnology Western blot 1:1000 nucleus
BCL-2 Santa Cruz Biotechnology Western blot 1:1000 cytoplasmic
β-actin Santa Cruz Biotechnology Western blot 1:2500
Goat anti-rabbit IgG Cell Signaling Technology Western blot Immunohistochemical 1:1000
1:100
Goat anti-rabbit Multiscience Immunofluorescence 1:100
IgG(H + L),FITC
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mated plate reader. Each treatment was conducted in
triplicates.
Flow cytometry assay
Flow cytometry (Beckman Coulter, Fullerton, California,
USA) was used to determine the apoptotic rate. The
HepG2.2.15 cells treated with the synthetic BM-06, or so-
rafenib alone, or BM-06 plus sorafenib?? were suspended in
a 500 μl binding buffer (Becton Dickinson, USA), incubated
with 5 μl Annexin V- FITC/PI (Becton Dickinson, USA)
and 5 μl propidium iodide (PI) (Becton Dickinson, USA)
for 15 minutes. Phosphatidyl serine translocation to the cell
surface serves as an indicator of early apoptotic cells; there-
fore, annexin V-positive and PI-negative cells were identi-
fied as apoptotic cells. The apoptotic rate was determined
using Cell Quest software (FCM, Becton Dickinson).
Cell invasion assay
HepG2.2.15 cells (2 × 104/well) were seeded and incu-
bated in 24-well at 37°C and 5% CO2 for 24 h.Transwell
chambers (Corning Inc., Corning, NY) were pretreated
with DMEM for 30 min. HepG2.2.15 Cells were treated
with 2.5% trypsin and suspended in a serum free DMEM
medium at a concentration of 1 × 106/ml prior to added
into each upper chamber (200 μl), and 600 μl DMEM
medium containing 20% FBS with different agents were
added into each lower chamber. Subsequently, the trans-
well chambers were incubated in a 37°C, 5% CO2, hu-
midified incubator for 48 h. The cells on the inner
surface of the filter membrane (8.0-μmpore size) were
removed. The cells on the lower surface of the mem-
brane were stained with crystal violet, and counted in
five random fields under a light microscope (200X).Hoechst staining
Treated cells were exposed to staining solution cont-
aining Hoechst 33258 (1 μg/ml) (Beyotime Institute of
Biotechnology, China) at 37°C for 20 min. Cells with
chromatin condensation were visualized and photographed
using a digital fluorescence microscope (Olympus) at
30 min after addition of the staining solution. Chromatin
condensation is the most characteristic feature of apop-
tosis. Cell apoptotic ratio was obtained by counting the
number of apoptotic cells with condensed nuclei amoung
all number of cells in six to eight randomly selected areas.
Nuclear and cytoplasmic extraction, Western blot analysis
Cells were seeded on a 6-well cell culture cluster (Corning
Inc.) at a concentration of 5 × 104/well in a volume of 2 ml,
and grown overnight. Cells were treated with 10 μg/ml
BM-06 or poly(I:C) or 10 μl PBS as control and incubated
for 24 h at 37°C. Briefy, cell pellets from a culture were in-
cubated in a hypotonic buffer [10 mM HEPES (pH 7.2),
10 mM KCl, 1.5 mM MgCl2, 0.1 mM EDTA, 20 mM NaF,
100 μM Na3VO4, and protease inhibitor mixture] for
30 min at 4°C on a rocking platform. Cells were homoge-
nized (Dounce, 30 strokes), and their nuclei were pelleted
by centrifugation (10 min × 14,000 rcf, 4°C). The super-
natant was saved as the cytosolic fraction, and nuclear
pellets were incubated in nuclear lysis buffer [10 mM
Tris–HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, and
1% Triton X-100] for 1 h at 4°C on a rocking platform.
The nuclear fraction was collected by centrifugation
(10 min × 14,000 rcf, 4°C).
Prior to immunoblotting, the rat HCC tissues were ho-
mogenized inlysate buffer containing protease inhibitors
and then pelleted via centrifugation at 13,000 g at 4°C.
The protein concentration in supernatants was measured
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SDS-PAGE gels for electrophoresis prior to electroblotting
proteins onto polyvinylidene difluoride (PVDF) membrane
(Immbilon, Millipore). The membrane was incubated with
anti-phospho-NF-κB p65, anti-TLR3, PCNA, Survivin and
BCL-2 (Table 2) primary antibodies at 4°C overnight fol-
lowing blockading non-specific binding sites in 5% non-fat
milk in TBST (Tris-buffered saline containing 0.1%
Tween-20). The membranes were washed 3 times in
TBST for 5 minutes and subsequently incubated with
secondary antibody for 2 hours at room temperature.
The bands on the membrane were displayed on the film
using a chemiluminescence system (Pierce, Rockford,
IL, USA). The bands on the film was scanned and mea-
sured for their density using Image Quant software
(Molecular Dynamics, Sunnyvale, CA, USA). The ratios
of NF- κB or TLR3 to β-actin were obtained.
Hematoxylin and eosin (HE) staining
After harvest, rat HCC tissues were formalin-fixed,
paraffin-embedded, and sections (4 μm thick) were pre-
pared for standard hematoxylin/eosin (H&E) and immu-
nohistochemical staining. The changes in histology were
assessed under a light microscope.
TUNEL(Terminal deoxynucleotidyl transferase-mediated
dUTP nick-end-labeling)detected apoptosis
TUNEL detection kit (Promega, USA) were employed for
the detection of neuronal apoptosis. In brief, paraffin-
embedded sections were deparaffinized and dehydrated.
After washing in PBS, sections were treated with 20 μg/mL
Proteinase K for 20 min. After washing in PBS thrice
(3 min for each), sections were rinsed with 0.3% Triton X-
100 for 10 min followed by washing in PBS. These sectionsFigure 1 TLR3 and NF-κB mRNA expressions. The expressions of TLR3 a
with five different dsRNAs. The values in the figure are normalized to PBS t
p < 0.05 compared to the BM-06 group.were incubated with TUNEL reaction mixture at 37°C for
1 h. Following washing in PBS thrice (3 min for each), sec-
tions were treated with HRP conjugated streptavidin (1:200;
Beijing Zhongshan Biotech Co., Ltd) at 37°C for 30 min.
After washing in PBS thrice (3 min for each), sections were
treated with 0.04% DAB and 0.03% H2O2 at room
temperature for visualization for 8–12 min. After washing
in water, counterstaining was done with hematoxylin
followed by mounting with resin. In the negative control,
TUNEL reaction mixture was replaced with PBS. The posi-
tive control sections were pre-treated with DNase I for
10 min followed by TUNEL staining. Cells with blue gran-
ules in the nucleus were regarded as positive for TUNEL. A
total of 100 cells were counted at a high magnification, and
the percentage of TUNEL positive cells was calculated.
Statistical analysis
Statistical analysis was performed using SPSS 17.0 for
Windows. The data were expressed as a mean ± SD. Dif-
ferences between groups were evaluated with ANOVA
or factorial design ANOVA and considered statistically
significant when P < 0.05. Nodules size was quantified
using Histolab 5.8 software (Microvision Instruments).
Results
Identification of the most effective dsRNAs activating TLR3
qRT-PCR results showed that both TLR3 and NF-κB were
expressed in HepG2.2.15 cells. Five dsRNAs, VEGFsiRNA
(si-VEGF), VEGFRsiRNA (si-VEGFR), 17ntdsRNA (17 bp),
BM-06 (23 bp)and poly(I:C), were chosen to identify
the most effective RNA nucleic acid in activation of TLR3
(Figure 1). qRT-PCR analyses showed that all five dsRNAs
resulted in increases in mRNA expression of both TLR3
and NF-κB in HepG2.2.15 cells, but dsRNA BM-06nd NF-κB were determined by RT-qPCR in HepG2.2.15 cells treated
reatment (1.00). *, p < 0.05 compared to the PBS control group; #,
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it was selected for further studies in the following experi-
ments. Since BM-06 or poly(I:C) bound to TLR3 will acti-
vate NF-κB and might regulate the nuclear-cytoplasmic
shuttling, NF-κB activity was checked by immunofluores-
cence after treating HepG2.2.15 with BM-06 or poly(I:C).
Immunofluorescence analysis showed BM-06 or poly(I:C)
treated HepG2.2.15 cells which expressed NF-κB levels pre-
dominantly in the nuclear fraction but fewer signals in the
cytoplasm (Figure 2A). To corroborate these findings,
we then tested the expression of endogenous NF-κB of
HepG2.2.15 cells under treatment with BM-06 or poly
(I:C). Western blot analysis showed BM-06 or poly(I:C)
treated HepG2.2.15 cells which expressed NF-κB levels
predominantly in the nuclear fraction but fewer signals
in the cytoplasm (Figure 2B).
Effect of combined use of BM-06 and sorafenib on
suppression of cell proliferation and invasion, and
induction of apoptosis
To determine whether synthetic BM-06 was able to affect
the proliferation of HepG2.2.15 cells, a CCK-8 assaywasFigure 2 Expression of NF-κB-p65 in HepG2.2.15 cells. A: Detection of
p65 (green) was expressed in HepG2.2.15 cells. BM-06 and poly(I:C) induced
ing in the nucleus fraction. The effect of BM-06 was better than the poly(I:C
HepG2.2.15 cells expressing NF-κB levels predominating in the cytoplasmic
protein (α-tubulin, cytoplasmic marker; lamin B, nuclear marker).performed on cells for 24 h, 48 h and 72 h (Figure 3A).
The results showed that the proliferative capacity of
HepG2.2.15 cells was significantly reduced by BM-06, sor-
efenib, poly(I:C) alone and BM-06 plus sorafenib com-
pared with the PBS control (P < 0.01; P < 0.01; P < 0.05;
P < 0.01, respectively), but the effect of combination was
the most significant among treated groups (p < 0.05).
Whether inhibition of cell proliferation by BM-06 re-
sulted from induction of apoptosis, and synergized by soraf-
enib. The annexin V-FITC/PI double staining and Hoechst
nuclear staining were used to display apoptotic cells. Typ-
ical apoptotic feature with Hoechst nuclear staining was
showed in Figure 2C. The results of flow cytometry showed
the percentage of annexin V-positive/ PI-negative cells was
significantly increased in all treated groups (Figure 3B). The
apoptotic rates in BM-06, sorafenib, poly(I:C) alone and
BM-06 plus sorafenib groups were 20.89%, 23.18%, 19.94%
and 26.14%, respectively, compared to as PBS control
(13.05%) (all P < 0.01), suggesting that all of these agents re-
sulted in decreased cell viability and increased cell apop-
tosis. Expectedly, apoptosis rate in the combination group
was higher over any of the other treated groups (P < 0.05).NF-κB-p65 expression in cells by immunofluorescence staining. NF-κB
TLR3-activated HepG2.2.15 cells expressing NF-κB levels predominat-
). B: Western blot analysis of dsRNA induced TLR3-activated
fraction. Cytoplasmic and nuclear fractions were assayed for NF-κB
Figure 3 Proliferative capacity and apoptotic cells were observed in all treated groups. A: The effects of BM-06 plus sorafenib group were
the most significant. A: Effect of 4 dsRNAs on proliferation of HepG2.2.15 cells. Growth curve of HepG2.2.15 cells was shown for each group. The
proliferation was assayed in triplicates at 24 h, 48 h, and 72 h post-treatment using CCK-8 kits. (*, P < 0.05 vs control group;#, P < 0.05 vs
BM-06 + sorafenib group) B: Apoptotic rates were measured in the treated HepG2.2.15 cells using a FACS analysis after Annexin-V-PI staining.
Percentages of apoptotic cells included both early- and late-stage apoptosis (AV+/PI- and AV+/PI+). Increased rates of apoptosis in the treated
groups were calculated relative to the PBS control. C: Apoptotic cells were observed in Hoechst nuclear staining (X200). D: Migrating cells were
observed in a Transwell chambers assay (X100).
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06, poly(I:C), sorafenib, BM-06 plus sorafenib was assessed
using a chamber precoated with Matrigel. After 48 h incu-
bation, the cells migrating through Matrigel were counted.
A significant decrease was found in the treated groups with
BM-06 (74 ± 08), sorafenib (56 ± 23), poly(I:C) (79 ± 04) or
BM-06 plus sorafenib (33 ± 16) as compared to the PBS
control (140 ± 11) (all P < 0.01), but migrating cells were re-
duced mostsignificantly in the BM-06 plus sorafenib group
(P < 0.01) (Figure 3D).
Growth inhibition by co-administration of BM-06 and
sorafenib in orthotopic SD HCC rat
After fed with 2-AAF for 14 weeks, the liver tissue were
observed after the rats were put to death and the tumor
nodules were marked by the yellow box. All rats were
carcinogenic success (Figure 4A). All SD rats revealedclear histological malignant transformation in the liver
(Figure 4B). BM-06, sorafenib, poly(I:C) or BM-06 plus so-
rafenib was administered into rats for 6 weeks at 2 more
weeks after 14 week of feedingwith 2-AAF. The treated
rats were sacrificed, and tumor size is mainly compared by
liver/body weight ratio of the mice (Figure 4A,C). The re-
sults showed that the tumor volumes of the HCC rats
treated with BM-06, sorafenib, poly(I:C) or BM-06 plus so-
rafenib were all significantly reduced when compared with
PBS controls (all p < 0.05). Comparison among treated
groups showed that the effect of BM-06 plus sorafenib
was most prominent on reducing tumor volume (p <
0.05). None of the other organs displayed pathological le-
sions, suggesting that these agents had no obvious cyto-
toxic effects on these organs of the experimental rats.
In addition, as shown in Figure 5, expression ratios of
PCNA (a proliferation marker), survivin and bcl-2 (both
Figure 4 The effects of dsRNAs on HCC of rats after 2-2AAF administration. A:The liver tissue were observed after the rats were put to
death and the tumor nodules were marked by the yellow box. B: Histological sections showing malignant features in livers of orthotopic SD rat
after fed with 2-AAF(X200). C: The ratios of tumors to body weights . *, p < 0.05 versus the PBS control group; #, p < 0.05 versus the BM-06 plus
sorafenib group.
Figure 5 Detection of the expression of PCNA, survivin and bcl-2 by western blot. Expressions of PCNA, survivin and bcl-2 in orthotopic SD
rat HCC . *, p < 0.05 compared to the PBS control group; #, p < 0.05 compared to the BM-06 plus sorafenib group.
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animals were greater than those of treated rats with
BM-06, sorafenib, poly(I:C) and BM-06 plus sorafenib
groups. As expected, combination resulted in more sig-
nificant decreases in the expression of PCNA, survivin
and bcl-2 (P < 0.05).
Furthermore , the results of TUNEL detection shown
that the apoptosis index in tumor cells of the control ani-
mals (14.39%) were obviously lower than those of treated
rats with BM-06, sorafenib, poly(I:C) and BM-06 plus
sorafenib groups (83.61%, 84.38%, 76.53% and 96.42%),
respectively (P < 0.05). And that combination resulted in
more significant increases the apoptosis index in tumor
cells (Figure 6).
As shown in Figure 7A, the RT-qPCR analyses showed
that the mRNA expression of TLR3, NF-κB, caspase-8
and IFN-γ in liver tumors of the HCC rats was all sig-
nificantly up-regulated by BM-06, poly I:C or BM-06
plus sorafenib. Western Blot assay revealed that in-
creases in protein expression of TLR3 and NF-κB were
observed in 3 groups treated with BM-06, poly I:C or
BM-06 plus sorafenib (Figure 7B) in comparison with
the PBS control (P < 0.05). In contrast, no difference in
the expressions of TLR3, NF-κB and IFN-γ was present
in sorafenib alone versus PBS , but an increased mRNA
expression of caspase-8 was found by sorafenib alone.Figure 6 TUNEL detected apoptosis in experimental groups. Apoptoti
stained in blue. (hybridization in situ × 400).Discussion
Molecular targeted therapies have created an encouraging
trend in the management of cancer. Sorafenib is a multiki-
nase inhibitor with a reported activity against Raf-1, B-Raf,
VEGFR2, PDGFR, c-Kit receptors, and other receptors
tyrosine kinases and serine threonine kinases [23]. Sorafe-
nib has been used in patients with advanced HCC and also
for those progressing after local therapies.Although pre-
clinical studies showed potent activity of sorafenib in de-
creasing HCC cell viability and inducing apoptosis, it also
has anti-angiogenic effect in vitro and in vivo, and antitu-
mor activity in xenograft models., This study was aim at
improving its efficacy by combining with other new drugs
and capable of suppressing tumors by involving in other
pathways.
TLR3 is a member of TLR family of innate immune
response receptors implicated in the initial host defense
against bacteria and viruses through the recognition of
specific pathogen-associated molecular ligands, and
stimulation of intracellular signaling, leading to the se-
cretion of inflammatory cytokines. Preclinical studies
have shown that dsRNAs as a TLR synergist can boost
innate immunity, augment antibody-dependent effect or
functions, and enhance adaptive immune responses
[24-26]. TLR3 may directly trigger apoptosis in certain
cancer cells. Therefore, TLR3 when activated by dsRNAsc nuclei were stained in brownish yellow, while normal nuclei were
Figure 7 The expression of TLR3, NF-κB, casepase-8 and IFN-γ in the tumors. (A) The mRNA levels of TLR3, NF-κB, casepase-8 and IFN-γ; (B)
TLR3 and NF-κB protein levels in liver tumors determined by Western Blot. Densitometric analyses of TLR3 and NF-κB proteins relative to β-actin.
Values are normalized to control cells (1.00). *, p < 0.05 compared to the PBS control group; #, p < 0.05 compared to BM-06 plus sprafenib group;
(C) Western blot showing the bands of TLR3 and IFN-γ proteins.
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[27]. Further studies will be conducted on the mecha-
nisms for dsRNA alone or in combination with sorafenib
in inhibiting tumors.
Several studies have demonstrated that TLR3 was
expressed on cell surface and in the cytoplasm of Kupffer
cells, hepatic stellate cells, hepatic immune cells, liver si-
nusoidal endothelial cells, and normal and tumor hepato-
cytes, [28-30]. Although some cancer cells, such as colonic
adenocarcinoma, lung cancer, breast cancer and melan-
oma, were also reported to express TLR3, the exact roles
of TLR3 in these cancer cells have yet to be elucidated
[21,31-33]. The TLR3 inflammatory pathway leads to the
NF-κB activation; whereas NF-κB is shown to induce pro–
IL-1β expression in hepatocytes, which is then activated by
caspase-8, an apoptotic pathway mediated by Rip3 [34],
leading to hepatocyte death. Several studies have shown
that in human hepatoma cell lines, unlike white blood
cells, TLR3 signaling is skewed towards the apoptotic path-
way [35]. In the present study, both HepG2.2.15 cells and
rat tumor tissue were able to express TLR3 and NF-κB.
We selected BM-06 dsRNA as a TLR3 synergist to stimu-
late TLR3 signaling, which leads to the activation of NF-κB
and upregulation of caspase-8 and IFN-γ, thus initiating
the TLR3 mediating inflammatory and apoptotic pathways.
Apoptosis is one of the mechanisms leading to cell death
when cells have sustained damage to their DNA orcytoskeleton [36]. After dsRNA treatment, HepG2.2.15
cell apoptosis was enhanced and activity was decreased. In
HCC rats treated with dsRNA, especially combination
with sorafenib, the increase in the expressions of TLR3,
NF-κB, caspase-8 and IFN-γ resulted in down-regulation
of survivin, bcl-2 and PCNA, which indicates increased
apoptosis and inhibition of tumor growth. TUNEL assay
confirmed that BM-06 can cause the HepG2.2.15 cell
apoptosis as well as sorafenib, the role of combination
BM-06 with Sorafenib was the most prominent and had
better antitumor action. Similarly, Khvalevsky [34] disco-
verd that during the initial regenerating phase following
partial hepatectomy, TLR3 signaling was induced in hepa-
tocytes, leading to activation of NF-κB and caspase-8, and
an increase in Rip3 protein levels. Upon activation,
caspase-8 cleaves effector caspases, which leads to cell
death by initiating apoptotic program. Yoneda et al. [37]
found cytoplasmic stimulation by transfected Poly I:C sig-
nificantly induced apoptosis accompanied by the down-
regulation of anti-apoptotic protein. Our findings suggest
that HCC cells were able to respond to these dsRNAs,
thus apoptosis was induced, and proliferationand invasion
were suppressed via binding TLR3 on the HCC cell sur-
face. TLR3-mediated signaling leads to the activation of
NF-κB and IRF-3 and expression of inflammatory associ-
ated with genes, including interferons [38]. In this study, a
level of INF-γ in the liver tumors was significantly
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identified as an inhibitor of endothelial cell proliferation
and a potent suppressor of tumor-associated neovasculari-
zation. Similarly, Mathieu studies showed [39] that treat-
ment of HCC mice with poly(I:C) resulted in suppression
of vasculature remodeling and liver tumor growth. These
effects might result from the activation of endothelial cell-
surface TLR3 and subsequent up-regulation of INF-γ and
interleukin-12. However, their investigations showed that
the INF-γ in mouse HCC liver extracts was most likely re-
leased by circulating or resident immune cells. Recent evi-
dence indicates that TLR3 may contribute to suppression
of tumor growth through the interferon-dependent activa-
tion of NK cells and expansion of Treg lymphocytes [40].
In short, the mechanism by which dsRNA activates TLR3
is very complex and, further studies will be conducted.
In this study, although the effect of BM-06 alone is less
significant than that of sorafenib alone in inhibition of
HCC proliferation, it is able to augment the role of sora-
fenib when combined with it. In addition, dsRNA could
play a role in inhibition of HCC through additional path-
ways, in which sorafenib might be ineffective that disrupts
more pathways in the complex tumor microenvironment.
Therefore, application of combination of BM-06 with so-
rafenib would be an ideal option in treatment of patients
with cancers because such a combination can simultan-
eously block signaling through the sorafenib MEK or
synergize TLR3 signaling. In addition, the combination of
both agents could attenuate systemic toxicity in animals.
The optimal length of dsRNA that can activate TLR3
in vivo is still unclear. In suppressing tumor vasculature
remodeling, unlike 21- and 23-nucleotide Luc siRNA, 7-,
13-, 16-, or 19-nucleotide versions failed to suppress chor-
oidal neovascularization (CNV) [41]. Thissuggests that
RNAs with a length at least 21 nucleotides are required to
activate TLR3, whereas longer dsRNA could be more cyto-
toxic. In the present study, BM-06, a length of 25 nucleo-
tide, was able to activate TLR3. Similarly, 17 nucleotide
dsRNA also activated TLR3, although the effect of shorter
dsRNA (17 nucleotide) was less than that of 25 nucleotide
dsRNA (BM-06). BM-06 was superior to poly(I:C) in inhi-
biting the proliferation and promoting apoptosis of
HepG2.2.15 cells, especially in combination with sorafe-
nib. These results show that stimulation of TLR3 by
dsRNA may be sequence length sensitity. Further investi-
gations will be focused on selection of more effective
TLR3 dsRNAs and exploration of more exact mechanisms
in activation of TLR3 in prevention of tumors.
As therapeutic agents, synthetic dsRNAs provide
some advantages over small inference RNA (siRNA), in-
cluding possibility for chemicalconformation that could
increase their efficiency and attenuate off target sup-
pression effects. Since synthetic siRNAs must be trans-
fected into the target cells through a vector, such asLipofectamine™ 2000 reagent, they always exhibit cytotox-
icity, which may limit their use in clinic. TLR3 ligand
dsRNA is able to inhibit tumor growth; therefore, it could
be used for adjuvant therapy in prevention of HCC.
Conclusion
dsRNA alone was capable of inhibiting the proliferation
of HepG2.2.15 cells and tumor growth of orthotopic
HCC SD rats, but the effect of combination of dsRNA
with sorafenib was more prominent. Combination ther-
apy can target multiple receptors and signaling path-
ways. Many of these combinations have been shown in
preclinical studies to have synergistic effect and may
block proposed resistant pathways.
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